APPLICATION
NDA020597
TYPE
NDA
ORIGINAL APPROVAL
1996-06-05
LATEST ACTION
2022-12-19
ROUTE
OPHTHALMIC
DOSAGE FORM
SOLUTION/DROPS
MARKETING STATUS
Prescription
Products
XALATAN · ReferencePrescription
LATANOPROST 0.005% · SOLUTION/DROPS · OPHTHALMIC
Approval history
2014-04-03Manufacturing (CMC) · Supplement 49 · priorityAP
2010-07-29Manufacturing (CMC) · Supplement 39AP
2002-06-21Manufacturing (CMC) · Supplement 24 · priorityAP
2001-05-14Manufacturing (CMC) · Supplement 22 · priorityAP
2001-04-23Manufacturing (CMC) · Supplement 20 · priorityAP
2000-12-26Labeling · Supplement 14 · standardAP
2000-12-11Manufacturing (CMC) · Supplement 17 · priorityAP
2000-11-09Manufacturing (CMC) · Supplement 16 · priorityAP
2000-08-25Labeling · Supplement 18 · standardAP
1999-10-08Labeling · Supplement 12 · standardAP
1999-07-16Labeling · Supplement 8 · standardAP
1999-03-22Labeling · Supplement 7 · standardAP
1998-12-09Manufacturing (CMC) · Supplement 2 · priorityAP
1998-11-01Manufacturing (CMC) · Supplement 6 · priorityAP
1998-06-23Labeling · Supplement 1 · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.